<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02411253</url>
  </required_header>
  <id_info>
    <org_study_id>P121001</org_study_id>
    <nct_id>NCT02411253</nct_id>
  </id_info>
  <brief_title>Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes</brief_title>
  <acronym>DIABIL-2</acronym>
  <official_title>European Phase-IIb Clinical Trial Evaluating Efficacy of Low Dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes DIABIL-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iltoo Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 1diabetes (T1D) is caused by autoimmune destruction of the pancreatic islet ß-cells,
      leading to an absolute deficiency in insulin.

      In health, regulatory T cells (Tregs) suppress immune responses against normal tissues, and
      likewise prevent autoimmune diseases. Tregs are insufficient in T1D.

      The investigators previously showed that administration of low doses of IL-2 induces
      selective expansion and activation of Tregs in mice and humans.

      The investigators hypothesize that Tregs expansion and activation with low doses of IL2 could
      block the ongoing autoimmune destruction of insulin producing cells in patients with recently
      diagnosed T1D.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Scientific justification:

      Clinical and preclinical studies, together with supportive mechanistic data showing that
      Tregs are activated by much lower IL-2 concentration than effector T cells (Teffs), provide a
      strong rationale for studying efficacy of low dose IL2 to stop the autoimmune destruction of
      insulin-secreting beta cells in patient with recently diagnosed with T1D.

      Primary objective:

        1. To evaluate efficacy of low dose IL-2 for the preservation of residual pancreatic β
           cells function

        2. To select the optimal regimen of administration of IL-2

      Primary assessment criterion:

      AUC (T0-T120) of serum C-peptide, determined after a mixed meal tolerance test at month 12,
      compared to baseline.

      Secondary objectives:

        1. To assess Tregs expansion after an induction period and during maintenance therapy

        2. To assess safety of IL-2 during the treatment period (1 year) and 1 year after its
           discontinuation

        3. To assess the relation between Tregs expansion and preservation of residual pancreatic β
           cells function

        4. To assess clinical and biological responses according to (i) pubertal stage group, (i)
           time from diagnosis to treatment initiation, (iii) biomarkers of responses

        5. To assess effects of IL-2 on disease-specific immune responses

        6. To identify biomarkers for predicting/monitoring safety and efficacy of IL-2.

      Secondary assessment criteria:

        -  Serum concentrations of C-peptide

        -  AUC (T0-T120) of serum C-peptide after a mixed meal tolerance test after treatment
           discontinuation

        -  Diabetic monitoring (insulin use)

        -  HbA1c and IDAA1c score

        -  Number of hypoglycaemic episodes (&lt; 0.5 g/L on capillary sample) over 15 days before
           each visit.

        -  Number of clinically significant symptomatic episodes of hypoglycaemia between each
           visit.

        -  Change in Tregs (expressed as percentage of CD4 and absolute numbers) at day 5 compared
           to baseline.

        -  Change in trough level of Tregs (%CD4+ and absolute numbers) at month 1, month 3, month
           6, month 9, month 12, compared to baseline; and then month 15 and 24 after treatment
           discontinuation.

        -  Change in Foxp3 gene methylation

        -  Cytokines and chemokines assays at day 5, month 1, month 3, month 6, month 9, and month
           12 compared to baseline and then month 15 and month 24 after treatment discontinuation.

        -  Transcriptome analysis.

        -  Genotyping at baseline

        -  Treg phenotype and functionality in adults and adolescents only including pStat5
           analysis

      Pharmacokinetic of IL2 will be performed (in patients from regimen A only) on day 1 at T0,
      T60min (1h), T120min (2h), T240min (4h), T360min (6h), T600min (10h), T1440min (24h=day2) on
      day 4, V8 (D29±1day) and V54 (day 351±3 days) at the same time points in 27 patients of
      regimen A.

      • Safety parameters will be evaluated by clinical examination (including height/weight and
      pubertal stage especially for children and adolescents), routine laboratory tests, ILT-101
      auto-antibodies, ancillary investigations and adverse event.

      Experimental design:

      This is a multicenter European, sequential-group, randomized, double-blind trial evaluating
      IL-2 versus placebo

      Population involved:

      Male or female, aged between 12 and 35 years, with type 1 diabetes diagnosed for less than
      two months.

      Number of subjects: 138

      Inclusion period: 12 months

      Duration of patient participation: 24 months (treatment period: 12 months, follow-up period:
      12months)

      Total duration of the study: 36 months

      Statistical analysis:

      The principal efficacy analysis will be drawn from the intention to treat group.

      The per-protocol analysis will be used to confirm the intention to treat analysis.

      For each regimen:

      - MMTT: C-peptide concentrations will be summarized by the AUC from T0 to T+120 min. Before
      statistical analysis, log (x+1) normalizing transformation will be used, and IL-2 and placebo
      treated patients will be compared using a mixed model of ANCOVA including baseline value as
      covariate and factor pubertal stage group.

      Quantitative endpoints will be analyzed using same methods as primary endpoint. Categorical
      endpoints will be analyzed using multivariate logistic regression models.

      Subgroups analyses: Response to treatment will be analysed according to criteria such as:

        -  Pubertal stage, age, gender, BMI…

        -  Biomarkers (identified in previous studies as predictive of patients' response to
           treatment)

      Funding source: European Commission under the Health Cooperation Programme of the Seventh
      Framework Programme (Grant Agreement n°305380-2).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (T0-T120) of serum C-peptide, determined after a mixed meal tolerance test at month 12, compared to baseline.</measure>
    <time_frame>Baseline, month12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of C-peptide</measure>
    <time_frame>month 3, month 6, month 9, month 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (T0-T120) of serum C-peptide after a mixed meal tolerance test after treatment discontinuation</measure>
    <time_frame>month 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetic monitoring (insulin use)</measure>
    <time_frame>baseline, Day 1, Day 5, month 1, month 3, month 6, month 9, month 12, month 15, month 18, month 21.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c and IDAA1c score</measure>
    <time_frame>baseline, month 3, month 6, month 9, month 12, month 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hypoglycaemic episodes (&lt; 0.5 g/L on capillary sample) over 15 days before each visit.</measure>
    <time_frame>baseline, Day 1, Day 5, month 1, month 3, month 6, month 9, month 12, month 15, month 18, month 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant symptomatic episodes of hypoglycaemia between each visit.</measure>
    <time_frame>baseline, Day 1, Day 5, month 1, month 3, month 6, month 9, month 12, month 15, month 18, month 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tregs (expressed as percentage of CD4 and absolute numbers) at day 5 compared to baseline.</measure>
    <time_frame>Baseline, Day 5.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in trough level of Tregs (%CD4+ and absolute numbers) at month 1, month 3, month 6, month 9, month 12, compared to baseline; and then month 15 and 24 after treatment discontinuation.</measure>
    <time_frame>Baseline, Month 1, Month 3, Month 6, Month 9, Month 12, Month 15, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Foxp3 gene methylation</measure>
    <time_frame>Day 1, Day 5, Month 1, Month 3, Month 6, Month 9, Month 12, Month 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines and chemokines assays at day 5, month 1, month 3, month 6, month 9, and month 12 compared to baseline and then month 15 and month 24 after treatment discontinuation.</measure>
    <time_frame>Baseline, Month 1, Month 3, Month 6, Month 9, Month 12, Month 15, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptome analysis.</measure>
    <time_frame>Baseline, Month 6, Month 12</time_frame>
    <description>Transcriptome analysis on whole PBMCs will allow analysis of changes in inflammation-related signatures, as already described in Saadoun et al. NEJM, 2011.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotyping at baseline</measure>
    <time_frame>baseline</time_frame>
    <description>Genotyping will be used to assess genetic variation (polymorphisms) associated with T1D, such as those linked to IL2RA, PTPN22, CTLA-4...</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treg phenotype and functionality in adults and adolescents only including pStat5 analysis</measure>
    <time_frame>Day 1, Day 5, Month 1, Month 3, Month 6, Month 9, Month 12, Month 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical examination.</measure>
    <time_frame>Baseline Day 1, Day 5, Month 1, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height/weight and pubertal stage especially for children and adolescents.</measure>
    <time_frame>Baseline, Month 12, Month 24</time_frame>
    <description>Based on Tanner staging (Tanner J. M. 1986).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Routine laboratory tests</measure>
    <time_frame>Baseline Day 1, Month 1, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 24</time_frame>
    <description>Biochemistry, Liver function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology</measure>
    <time_frame>Baseline Day 1, Day 5, Month 1, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of IL-2 auto-antibodies</measure>
    <time_frame>Day1, Month 6, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T cells repertory</measure>
    <time_frame>Day 1, Day 5, Month 6, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal microbiota.</measure>
    <time_frame>Baseline, Month 6, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event.</measure>
    <time_frame>Baseline, Day 1, 2, 3, 4, 5, Month 1, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 24</time_frame>
    <description>Throughout the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>rhIL-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 MIU/m²/day of IL2 with a maximum of 1MIU/day in a volume of 1 ml for children and adolescents,
1MIU/day for adults.
Subcutaneous injection every day (5 days) then:
Regimen A injection every two weeks between D15 and D351,
Regimen B injections every week between D15 and D351</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo with a identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 days) then:
Regimen A injection every two weeks between D15 and D351
Regimen B injections every week between D15 and D351</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhIL-2</intervention_name>
    <description>Subcutaneous injections of IL2 according to regimen A Subcutaneous injections of IL2 according to regimen B</description>
    <arm_group_label>rhIL-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injections of Placebo according to regimen A Subcutaneous injections of Placebo according to regimen B</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Age 12-35 years old.

          -  Male or female both using effective methods of contraception during treatment if
             sexually active.

          -  Specifically; Females (if sexually active) with childbearing potential must use
             contraceptive methods that are considered as highly-effective (pearl index &lt; 1). The
             following methods are acceptable: Oral , injectable, or implanted hormonal
             contraceptives (with the exception of oral minipills ie low-dose gestagens which are
             not acceptable (lynestrenol and norestisteron), Intrauterine device, Intrauterine
             system (for example, progestin-releasing toit),

          -  beta HCG negative at inclusion;

          -  With type-1 diabetes:

          -  Newly diagnosed (ADA criteria, see annexe 19.6) at most two months between insulin
             initiation and anticipated start of experimental treatment.

          -  Positive for one or more of the autoantibodies typically associated with T1D
             (anti-islet, -insulin, -GAD, -IA2, -ZnT8)

          -  With a detectable peak C-peptide concentration during a standardised MMTT at Visit
             MMTT (≥0.2pmol/ml);

          -  patients with a stable blood glucose level and seric glycaemia between 60 mg/dL and
             250 mg/dL verified at MMTT visit

          -  Absence of clinically significant abnormal laboratory values (out of range and
             associated with clinical symptoms or signs) in haematology, biochemistry, thyroid,
             liver and kidney function;

          -  Normal cardiac function: no documented history of heart disease and absence of family
             history of sudden death, normal ECG especially QTc duration within normal value
             (&lt;480ms);

          -  Free, informed and written consent, signed by the patient and investigator before any
             Study examination. If the patient is a minor by child and both parents or child and
             the legal representative in case only one parent is alive. (Journal officiel des
             communautés européennes (1.5.2001)

          -  NB: patient with history of thyroidism on treatment at the inclusion and with normal
             thyroid hormone values (TSH+T4) can be included.

        Exclusion criteria

          -  Children under the age of 12 years old cannot be included

          -  Patient who, before inclusion, have been treated with other anti-diabetic medication
             than Insulin for more than 3 months consecutively

          -  Chronic adrenal insufficiency known or fasting ACTH ≥2.5 ULN normal at inclusion after
             control;

          -  Anti TPO present at inclusion and abnormal TSH and T4

          -  Anti-transglutaminase positive at inclusion

          -  Hypersensitivity to the active substance or to any of the excipients

          -  Any major health problem including: any major auto-immune/auto-inflammatory disease
             (other than type 1 diabetes) present at inclusion, any significant respiratory disease
             (such as moderate or severe COPD or asthma) requiring the chronic use of
             corticosteroids (whatever route of administration) and serious digestive malfunctions.

          -  Patient with existing malignancy or history of malignancy

          -  Major psychosocial instability with expected lack of compliance with insulin
             treatment, psychiatric pathology of patient or parents, or major problems of family
             dynamics;

          -  Signs of active infection;

          -  Any patient with obesity defined as BMI ≥ 35

          -  Existence of a serious malfunction of a vital organ;

          -  History of organ allograft;

          -  Use of treatments not allowed in the Study (see Section 8.4.2);

          -  Vaccination with alive attenuated virus within 4 weeks of the first injection of the
             induction period and during the whole maintenance period

          -  Pregnant female (confirmed by laboratory testing) or lactating

          -  Participation in another clinical trial in the previous 3 months;

          -  Lack of affiliation to a social security scheme (as a beneficiary or assignee).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Klatzmann, MD, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Klatzmann, MD, Ph.D.</last_name>
    <phone>+33.1.42.17.74.61</phone>
    <email>david.klatzmann@upmc.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pediatric Department, Centre Hospitalier Régional de la Citadelle</name>
      <address>
        <city>Liège</city>
        <state>Province de Liège</state>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramona C NICOLESCU, Dr</last_name>
      <phone>0032 42 25 71 02</phone>
      <email>rcnicolescu@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigations Cliniques, CHU-HOPITAL HAUTEPIERRE</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigations Cliniques, HÔPITAL CIVIL</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Service de pédiatrie 1CHU de HAUTEPIERRE</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie MANSILLA</last_name>
      <email>marie.mansilla@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Structure d'Endocrinologie-Diabète-Nutrition et Addictologie HOPITAUX UNIVERSITAIRES NHC</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <zip>BP421 - 67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence KESSLER, Pr</last_name>
      <email>laurence.kessler@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endocrinologie et diabétologie pédiatrique, Hôpital des Enfants - CHU-Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <state>Aquitaine</state>
        <zip>33076 Bordeaux Cedex</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Service d'endocrinologie, diabétologie, maladies métaboliques, et nutrition, CHU de Bordeaux, Hôpital Haut Levêque</name>
      <address>
        <city>Pessac</city>
        <state>Aquitaine</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent RIGALLEAU, Pr.</last_name>
      <phone>06 63 24 45 51</phone>
      <email>vincent.rigalleau@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d' Endocrinologie HOPITAL CAVALE BLANCHE</name>
      <address>
        <city>Brest</city>
        <state>Brittany</state>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel SONNET, Pr</last_name>
      <phone>02 98 34 71 19</phone>
      <email>emmanuel.sonnet@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Pédiatrie, HOPITAL MORVAN</name>
      <address>
        <city>Brest</city>
        <state>Brittany</state>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal METZ, MD</last_name>
      <phone>00 33 2 29 02 00 04</phone>
      <email>chantal.metz@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Pédiatrie CHRU DE NANTES</name>
      <address>
        <city>Nantes</city>
        <state>Brittany</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine BARON, Pr</last_name>
      <email>sabine.baron@chu-nantes.fr</email>
    </contact>
    <contact_backup>
      <last_name>celine ROBIN, CRC</last_name>
      <phone>02 40 08 78 04</phone>
      <email>celine.robin@chu-nantes.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Service d' Endocrinologie Diabétologie CHRU DE RENNES</name>
      <address>
        <city>Rennes</city>
        <state>Brittany</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc De Kerdanet, Pr</last_name>
      <phone>00 33 2 99 26 71 36</phone>
      <email>marc.de.kerdanet@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Médecine pédiatrique, CHU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <state>Franche-Compté</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Marie Bertrand, Dr.</last_name>
      <phone>03 81 21 81 34</phone>
      <email>bertrand.anne-marie@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Diabétologie -Endocrinologie, CHU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <state>Franche-Comté</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Borot, Dr.</last_name>
      <phone>06 89 16 22 46</phone>
      <email>sophie.borot@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service MME, ENDOCRINOLOGIE, GHU CAREMEAU</name>
      <address>
        <city>Nimes Cedex 9</city>
        <state>Gard</state>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valeria COSMA, Pr</last_name>
      <email>valeria.COSMA@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIC Paris-Est (Adultes), Hôpitaux Universitaires Pitié-Salpêtrière, Charles Foix</name>
      <address>
        <city>Paris</city>
        <state>Ile de france</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CIC pédiatrique Hôpital Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <state>Ile De france</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endocrinologie gynécologie diabétologie pédiatriques, Hôpital Universitaire Necker Enfants Malades.</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Polak, Pr</last_name>
      <phone>+33 (0)1 44 49 48 02</phone>
      <email>michel.polak@nck.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIC Pédiatrique, Hôpital d'enfants Robert Debré</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut E3M, Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <state>Ile-de France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnés Hartemann, Pr.</last_name>
      <phone>01 42 17 81 18</phone>
      <phone_ext>80 70</phone_ext>
      <email>agnes.hartemann@psl.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie Pédiatrique, Hôpital d'enfants Robert Debré</name>
      <address>
        <city>Paris</city>
        <state>Ile-de France</state>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Claude CAREL, Pr</last_name>
      <phone>01 40 03 53 03</phone>
      <email>jean-claude.carel@inserm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Diabétologie Endocrinologie Hôpital LARIBOISIERE</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-François Gautier, Pr</last_name>
      <email>jean-francois.gautier@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Pédiatrie - Pôle femmes enfants, CHU de Nîmes, Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nïmes</city>
        <state>Languedoc-Roussillon</state>
        <zip>30029 Cédex 9</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tu Anh TRAN, Pr.</last_name>
      <phone>04 66 68 32 84</phone>
      <phone_ext>32 85</phone_ext>
      <email>tu.anh.tran@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Pédiatrie - Gastro-entérologie, Hépatologie, Nutrition, Diabétologie, Hôpital des Enfants Pôle Enfants</name>
      <address>
        <city>Toulouse</city>
        <state>Midi Pyrénnées</state>
        <zip>31059 Toulouse cedex 9</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire LE TALLEC, Dr</last_name>
      <phone>05 34 55 85 64</phone>
      <email>letallec.c@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille, Hôpital Claude Huriez Service d'endocrinologie</name>
      <address>
        <city>Lille</city>
        <state>Nord-Pas-de-Calais</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre FONTAINE</last_name>
      <phone>03 20 44 45 13</phone>
      <email>pierre.fontaine@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'endocrinologie-diabétologie gynécologie pédiatriques, CHRU de Lille, Hôpital Jeanne de Flandre,</name>
      <address>
        <city>Lille</city>
        <state>Nord-Pas-de-Calais</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques WEILL, Pr.</last_name>
      <phone>03 20 44 46 95</phone>
      <email>Jacques.WEILL@CHRU-LILLE.FR</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d' Endocrinologie, maladies métaboliques HOPITAL NORD</name>
      <address>
        <city>Marseille</city>
        <state>Paca</state>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne DUTOUR, Pr</last_name>
      <email>AnneEveSophie.MEYER@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Nutrition - Maladies Métaboliques - Endocrinologie HOPITAL DE LA CONCEPTION</name>
      <address>
        <city>Marseille</city>
        <state>Paca</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>René VALERO, Pr</last_name>
      <email>rene.valero@ap-hm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Catherine ZEVACO, Pr</last_name>
      <email>Catherine.ZEVACO@ap-hm.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hopital G&amp;R Laënnec , Endocrinologie, Maladies Métaboliques et Nutrition</name>
      <address>
        <city>Saint Herblain</city>
        <state>Pays de la Loire</state>
        <zip>44093 NANTES Cedex 1</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucy Chaillous, Pr</last_name>
      <email>lucy.chaillous@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unité d'Endocrinologie et Diabétologie Pédiatriques, CHU de Marseille, Hôpital La Timone Enfants</name>
      <address>
        <city>Marseille</city>
        <state>Provence-Alpes-Côte-d'Azur</state>
        <zip>13385 Marseille Cedex 5</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Reynaud, Pr.</last_name>
      <phone>04 91 38 80 40</phone>
      <phone_ext>67 30</phone_ext>
      <email>Rachel.REYNAUD@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endocrinologie-Diabétologie-Maladies de la nutrition, Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Lyon</city>
        <state>Rhones-Alpes</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles THIVOLET, Pr.</last_name>
      <phone>04 78 86 14 87</phone>
      <email>charles.thivolet@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie pédiatrique - HFME</name>
      <address>
        <city>Lyon-bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Delphine Bernoux, Pr</last_name>
      <phone>00 33 4 72 35 79 99</phone>
      <email>delphine.bernoux@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Endocrinology and Diabetology, Department of Internal Medicine II, University Hospital of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jochen SEUFERT, Pr</last_name>
      <phone>Tel. +49 761 270 34200</phone>
      <email>jochen.seufert@uniklinik-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Endocrinology, Diabetology and Metabolic Diseases, University Hospital of Freiburg, Department for children and adolescents</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karl O SCHWAB, Pr</last_name>
      <phone>+49 761 270 44140</phone>
      <email>karl.otfried.schwab@uniklinik-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Diabetes Research, Helmholtz Zentrum München</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>D 80804</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette G ZIEGLER, Pr</last_name>
      <phone>00 49 089 3187 2896</phone>
      <email>anette-g.ziegler@helmholtz-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Diabetes Research, Helmholtz Zentrum München</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>D 80804</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katharina Warncke, Pr</last_name>
      <phone>00 49 089 3187 2896</phone>
      <email>Katharina.Warncke@lrz.tu-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Pediatric and Adolescent Diabetes Care and Research</name>
      <address>
        <city>Rotterdam</city>
        <state>Randstad Holland</state>
        <zip>3011 TG Rotterdam</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henk-Jan AANSTOOT, Dr.</last_name>
      <phone>+31-10-280-7277</phone>
      <phone_ext>9872</phone_ext>
      <email>h.j.aanstoot@diabeter.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Clinical Sciences Lund University, Skåne University Hospital.</name>
      <address>
        <city>Malmö</city>
        <state>Öresund Region</state>
        <zip>205 02 Malmö</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corrado M. CILIO, Pr.</last_name>
      <phone>+46-70 43 30338</phone>
      <phone_ext>+46-40-391127</phone_ext>
      <email>corrado.cilio@med.lu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endocrinology and Diabetes department, University Hospital of Basel</name>
      <address>
        <city>Basel</city>
        <state>Bâle-Ville</state>
        <zip>4031 Basel</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Donath, Pr.</last_name>
      <email>mdonath@uhbs.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>April 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2015</study_first_posted>
  <last_update_submitted>November 8, 2016</last_update_submitted>
  <last_update_submitted_qc>November 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IL2</keyword>
  <keyword>Interleukin 2</keyword>
  <keyword>IL-2</keyword>
  <keyword>Auto-immune disease</keyword>
  <keyword>Insulin</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Regulatory T cells</keyword>
  <keyword>Treg</keyword>
  <keyword>Immunoregulation</keyword>
  <keyword>Immune tolerance</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

